Rockwell Medical Stock (NASDAQ:RMTI)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$3.79

52W Range

$1.16 - $4.57

50D Avg

$3.58

200D Avg

$2.17

Market Cap

$120.71M

Avg Vol (3M)

$556.56K

Beta

1.49

Div Yield

-

RMTI Company Profile


Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

237

IPO Date

Jan 27, 1998

Website

RMTI Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Drug Revenue$2.34M--
Concentrate Products$81.27M--
Upfront Fee-$2.50M$1.90M

Fiscal year ends in Dec 23 | Currency in USD

RMTI Financial Summary


Dec 23Dec 22Dec 21
Revenue$83.61M$72.81M$61.93M
Operating Income$-6.67M$-16.78M$-30.34M
Net Income$-8.44M$-20.58M$-35.03M
EBITDA$-6.67M$-16.75M$-27.80M
Basic EPS-$-2.09$-4.11
Diluted EPS-$-2.09$-4.11

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 08, 24 | 1:33 PM
Q1 24May 14, 24 | 12:00 AM
Q4 23Mar 21, 24 | 9:36 AM

Peer Comparison


TickerCompany
ITCIIntra-Cellular Therapies, Inc.
BFRIBiofrontera Inc.
EVOKEvoke Pharma, Inc.
ACORAcorda Therapeutics, Inc.
ANIPANI Pharmaceuticals, Inc.
AQSTAquestive Therapeutics, Inc.
LFCRLifecore Biomedical, Inc.
PAHCPhibro Animal Health Corporation
GHSIGuardion Health Sciences, Inc.
RGCRegencell Bioscience Holdings Limited
IXHLIncannex Healthcare Limited
SSICSilver Spike Investment Corp.
ACRXTalphera, Inc.
HUGEFSD Pharma Inc.
CPIXCumberland Pharmaceuticals Inc.
PROCProcaps Group S.A.
ADMPAdamis Pharmaceuticals Corporation
LSDILucy Scientific Discovery Inc.
AGRXAgile Therapeutics, Inc.
KMDAKamada Ltd.
COLLCollegium Pharmaceutical, Inc.
SXTCChina SXT Pharmaceuticals, Inc.
EGRXEagle Pharmaceuticals, Inc.